Cardiorespiratory Fitness Tied to Reduced Cancer Incidence, Mortality in Men
Moderate, high CRF linked to lower colon cancer incidence; low, moderate, high CRF linked to lower prostate cancer mortality.
Diagnosis & Disease Information
FDA Approves Talzenna for Metastatic, Castration-Resistant Prostate Cancer
Significant radiographic progression-free survival seen for homologous recombination repair gene mutation, including with BRCA mutation.
EBRT Does Not Improve Upon Brachytherapy in Intermediate-Risk Prostate Cancer
EBRT plus brachytherapy does not improve outcomes over brachytherapy alone in patients with intermediate-risk prostate cancer, a phase 3 trial suggests.
No Benefit With Flutamide Plus Vaccine vs Flutamide Alone for Nonmetastatic CRPC
The primary endpoint was not met in a study of flutamide with or without the PROSTVAC vaccine in patients with nonmetastatic castration-resistant prostate cancer.
Lynparza Combo Approved for BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer
Lynparza is a poly polymerase inhibitor.
Adding Talazoparib to Enzalutamide Appears Beneficial in mCRPC With HRR Mutations
Adding talazoparib to first-line treatment with enzalutamide improves rPFS in patients with HRR-deficient mCRPC, a phase 3 trial suggests.
Second-Generation Antiandrogens Linked to Falls, Cognitive Toxicity in Prostate Cancer Patients
Prostate cancer patients treated with second-generation antiandrogens may have an increased risk of falls, fatigue, and cognitive toxicity.
Cancer Death Rates Vary Across Congressional Districts
Cancer death rates in the US have declined in recent years, but the declines vary by congressional district, a study suggests.
Enzalutamide Ups Metastasis-Free Survival in nmHSPC
Investigators report results from the phase 3 randomized EMBARK trial.
Transgender Women May Be Underdiagnosed With Prostate Cancer
Findings suggest link to more aggressive disease among estrogen users, but researchers say larger studies needed.
- Loading...
Loading...
Next post in Prostate Cancer
Loading... 
Loading...